Study of DF6215 in Patients With Advanced Solid Tumors

NCT06108479 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

35

Enrollment

INDUSTRY

Sponsor class

Conditions

Solid Tumor, Adult
Solid Tumor Cancer

Interventions

DRUG: DF6215
DRUG: pembrolizumab
DRUG: KEYTRUDA®

Sponsor

Dragonfly Therapeutics

Collaborators

[object Object]